Arunan Kaliyaperumal

Arunan Kaliyaperumal has a wealth of experience in the field of preclinical biology. Arunan began their career in 1990 as a Scientist at the National Institute of Immunology, where they conducted clinical evaluations of protein conjugate vaccines and established a reagent reference center as part of a United Nations Development Program. In 1992, they became a Research Associate at the University of Chicago's Ben May Institute. Two years later, they moved to Northwestern University's Feinberg School of Medicine, where they served as an Assistant Professor and worked on the localization of major nucleosome specific T cells of Systemic Lupus Erythematosus. In 2001, they became a Lead Scientist at PowderJect Vaccines (Chiron Vaccines Company), where they were responsible for immunology and bioanalytical work for the development of DNA for vaccines against oncology targets. In 2004, they joined Amgen as a Senior Scientist and Research Scientist III, and in 2009 they were promoted to Principal Scientist. In this role, they were the scientific investigator for research, preclinical, clinical and post-marketed products for regulatory filings. In 2017, Arunan joined Eli Lilly and Company as a Research Fellow, where they built a group for early pre-clinical development of biologics risk assessment and mitigation. Finally, in 2021 they became the VP of Preclinical Biology at ReCode Therapeutics.

Arunan Kaliyaperumal began their educational journey in 1982 when they obtained a Master's Degree in Chemistry from the Indian Institute of Technology, Roorkee. Arunan then went on to pursue a Doctor of Philosophy (Ph.D.) in Immunology at the National Institute of Immunology, which they completed in 1992. In 2019, Arunan Kaliyaperumal obtained two certifications from LinkedIn: Building High-Performance Teams and Managing High Potentials.